Pfizer Medicine Reduces The Risk of Death from Covid-19 by 37%, Reveals Study Carried Out in Brazil

Einstein's research in partnership with the pharmacist was carried out with hospitalized patients


A research study conducted by the Israeli Teaching and Research Institute, which is linked to the Hospital Israelita Albert Einstein, reveals that the administration of the drug ​tofacitinib showed a 37% reduction in the risk of death and respiratory failure in patients hospitalized because of Covid-19.

Marketed as Xeljanz, the drug is currently prescribed for the treatment of rheumatoid arthritis, psoriatic arthritis and ulcerative colitis.

The study developed by Einstein in partnership with Pfizer, a pharmaceutical company that produces tofacitinib, was carried out in a group of 289 adult patients hospitalized in 15 treatment centers throughout the country.

The results showed a lower incidence of death or respiratory failure due to the novel coronavirus among patients who received the drug (18.1%) compared to those who received the placebo (29.0%). The research observed the participants for a period of 28 days and administered tofacitinib orally.

Xeljanz is considered a high-cost drug and is made available by the SUS. Pfizer does reveal prices, but it can be found in pharmacies for over R$ 5 thousand.

Translated by Kiratiana Freelon

Read the article in the original language